2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
Recent News
Read ArticleNew and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults, alongside a newly developed companion guideline focused specifically on juvenile axial spondyloarthritis.
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
https://t.co/6uLv16aOcX https://t.co/a3NxMdnI9F
Dr. John Cush @RheumNow ( View Tweet)
RHEUMATOLOGIST POLL> ?How valuable is a Lupus Nephritis Indication when treating NON-RENAL lupus? Answer here>> https://t.co/K4aikzZRmY https://t.co/60wM3XJE8n
Dr. John Cush @RheumNow ( View Tweet)
No Fetal Risks with First Trimester NSAID Use
PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital https://t.co/ZVUOizbcdg
Dr. John Cush @RheumNow ( View Tweet)
B cell Targeting in SLE
MedPage Today
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
Read Article
2-Gene Blood Test for Kawasaki Disease in Febrile Children
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Read Article
Steroids in SpA? DBRPCT of 94 (nonPsA) SpA pts w/ peripheral arthritis (SJC ≥ 2) placebo or steroids (GC) (csDMARDs background allowed). 76% male, age 32 yrs, TJC 10, SJC 3.6. Wk 24 there was no signif diff betw groups for ACR 50, ACR70 or PSpARC outcomes. https://t.co/snJovW31Uk
Dr. John Cush @RheumNow ( View Tweet)
Retrospective study of 116 BL KOA (Kellgren–Lawrence I–II) pts rx w/ three PRP injx (n 58) or NSAIDs +/- IAhyaluronic acid (n 58). After 5 yrs there was no signif. difference in VAS, WOMAC, and SF-36, with both groups worsening. https://t.co/KDSMTvEl59 https://t.co/lgHOsppIU3
Dr. John Cush @RheumNow ( View Tweet)
Mentors & Mentees can do great things!!! https://t.co/gdf5laCuCm
Dr. John Cush @RheumNow ( View Tweet)
Chinese study of 341 RA pts, half managed post D/C w/ nurse led AI interactive platform vs usual care. @ 6 mos AI platform group had signif better outcomes - DAS28 (-0.77 vs -0.27), HAQ functional status, medication adherence (90 vs 80%), and pt satisfaction (96 vs 76%) https://t.co/SrDgUuAWB3
Dr. John Cush @RheumNow ( View Tweet)
Korean insurance claims study of 50 600 adults w/ newly dx #RA - Persistent low-income significantly increased mortality risk, especially if RA <65 yrs or rural residence; Sustained high-income status provided a protective effect across all age group https://t.co/OIhvz489Ar https://t.co/lYwgc2Ty3n
Dr. John Cush @RheumNow ( View Tweet)
JAMA Review on Low Back Pain
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/liEitQ2ACf
Dr. John Cush @RheumNow ( View Tweet)
Can AI Predict Progression to RA?
Dr. Jonathan Kay reports on abstract POS0967 at EULAR 2026 in London
https://t.co/m8wvp93mTA https://t.co/ADZa9C4068
Dr. John Cush @RheumNow ( View Tweet)
No Fetal Risks with First Trimester NSAID Use
PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk.
Read Article
Where are we with Biomarkers in Rheumatoid Arthritis?
Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).
Read Article
Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
https://t.co/hOfXR39s3H https://t.co/X7skwKrCc3
Dr. John Cush @RheumNow ( View Tweet)
Missed a session at EULAR 2026?
No problem.
The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/YZ7oRNXfqU
Dr. John Cush @RheumNow ( View Tweet)
Type 2 diabetes pts taking semaglutide have a 15% lower risk of fractures. Endocrine society abstract EHR study of 26K SEM vs controls. Previous studies have linked rapid weight loss to a greater risk of fractures https://t.co/7nRYST5fPX https://t.co/kJ9Y5gcXFD https://t.co/AD6iVfkK3w
Links:
Dr. John Cush @RheumNow ( View Tweet)
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/Q1M4vgN0aD
Dr. John Cush @RheumNow ( View Tweet)
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
